Nephronomics

Executive Summary

Nephronomics is a precision medicine biotechnology company redefining cardio-kidney-metabolic (CKM) and primary renal disease care. Founded in 2018 and based in San Francisco, the company vertically integrates a robust clinical and genomic database with machine learning models to identify disease subtypes and develop targeted therapies. As a joint venture with Fresenius Medical Care, Nephronomics leverages Fresenius's extensive patient network and real-world data to accelerate discovery and validation. The company's approach addresses the high heterogeneity of kidney diseases, aiming to deliver more effective, personalized treatments that could improve outcomes and reduce healthcare costs. Currently operating at the preclinical stage, Nephronomics is positioned to capitalize on the growing convergence of AI and genomics in nephrology, a field ripe for innovation.

Upcoming Catalysts (preview)

• Q3 2026Publication of machine learning model validation data in peer-reviewed journal70% success
• TBDFirst patient dosed in Phase 1 trial for lead CKM therapy30% success
• TBDStrategic partnership or licensing deal to expand therapeutic pipeline40% success